NAPRA drug schedule update

The National Association of Pharmacy Regulatory Authorities (NAPRA) has announced revisions to the National Drug Schedules.

The recommendations were made by the National Drug Scheduling Advisory Committee include that

• acetaminophen and ibuprofen in oral, fixed-dose combinations, in package sizes containing 20,000 mg or less of acetaminophen and 6,000 mg or less of ibuprofen, be granted Schedule III status; and
• acetaminophen and ibuprofen in oral, fixed-dose combinations, in package sizes containing either more than 20,000 mg of acetaminophen or more than 6,000 mg of ibuprofen, be granted Schedule II status.

The revisions were effective July 28, 2020, and the National Drug Schedules have been revised accordingly.

For more information, visit the NAPRA website.